Tonix Pharmaceuticals Implements 1-for-100 Stock Split Strategy
Overview of the Reverse Stock Split by Tonix Pharmaceuticals
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a renowned biopharmaceutical company, has made a significant announcement regarding a 1-for-100 reverse stock split for its common stock. This strategic move is aimed at enhancing the trading value of its shares, which will take effect on the market as of the opening of trading on February 5, 2025.
Motivation Behind the Stock Split
The primary objective of the reverse stock split is to elevate the per-share trading price of Tonix’s common stock. This increase is essential to meet the $1.00 minimum bid price requirement necessary for maintaining its listing on The NASDAQ Capital Market. Under the new arrangement, each hundred pre-split shares will convert into one share post-split, and a new CUSIP number will be assigned to these stocks. Tonix will retain its trading symbol, “TNXP,” on the exchange after the split.
Impact on Shareholders and Trading Process
As part of this reverse split, all common stock that shareholders currently hold will undergo this transformation, including shares obtainable through warrants and stock options. It's important to note that the total number of authorized shares will remain unchanged according to Nevada law, as established by the approval received from shareholders.
About Tonix Pharmaceuticals
Tonix Pharmaceuticals is dedicated to advancing innovative therapies in pain management and vaccines for various public health challenges. One of the key focuses of the company is TNX-102 SL, a candidate aimed at addressing fibromyalgia. Tonix plans to submit a New Drug Application (NDA) for TNX-102 SL, based on positive outcomes from two significant Phase 3 studies, enhancing the potential for receiving a marketing authorization soon since the FDA has also designated it with Fast Track status. Further, Tonix is exploring treatments for acute stress reactions and disorders through this candidate with related studies being conducted at the University of North Carolina.
Research and Development Initiatives
Tonix has a rich pipeline, including TNX-1300, a biologic in Phase 2 development targeting cocaine intoxication. This candidate has received the FDA Breakthrough Therapy designation, allowing it to move with urgency through the regulatory process. Additionally, the company is focused on biologic treatments for conditions like autoimmune disorders, organ transplant rejection, and cancer, highlighting its diverse therapeutic ambitions.
Recent Partnerships and Projects
In a notable partnership, Tonix secured funding from the U.S. Department of Defense's Defense Threat Reduction Agency (DTRA) to develop TNX-4200, which aims to prevent or treat infections through broad-spectrum antiviral action. This project showcases Tonix’s commitment to supporting the health and readiness of military personnel against biological threats, demonstrating its capacity to tackle critical public health issues.
Current Product Offerings
Tonix also operates Tonix Medicines, which markets products such as Zembrace® SymTouch® and Tosymra®. These medications are specifically designed for treating acute migraines in adults with promising preliminary data backing their effectiveness. However, these products are not intended for use in preventing migraines, emphasizing their targeted application in acute scenarios.
Investor Relations and Contact Details
Investors looking to gather more insights about Tonix Pharmaceuticals can contact the Investor Relations team. Jessica Morris can be reached at (862) 799-8599 or via email at investor.relations@tonixpharma.com. Peter Vozzo of ICR Healthcare is also available at (443) 213-0505 or peter.vozzo@icrhealthcare.com for further inquiries.
Frequently Asked Questions
What does the reverse stock split mean for shareholders?
The reverse stock split means that shareholders will receive fewer shares, but the value of each share will theoretically increase, maintaining the overall value of their investment.
Why is Tonix Pharmaceuticals implementing this reverse stock split?
The company is implementing the split to raise its stock price to meet the NASDAQ minimum bid price requirement.
When will the split become effective?
The reverse stock split will take effect for trading purposes on February 5, 2025.
Are there risks associated with the reverse stock split?
While the split is aimed at improving stock performance, it doesn't guarantee price appreciation and still involves market risks.
Where can I find more information about Tonix Pharmaceuticals?
Investors can visit www.tonixpharma.com for detailed information about the company and its developments.
About The Author
Contact Henry Turner privately here. Or send an email with ATTN: Henry Turner as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
